Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVD for Untreated Classical Hodgkin Lymphoma
NCT03331341Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by University of Washington. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03331341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331341.